Pharmacists in Cuba, MO Accepting Medicare

9 Pharmacists found. Showing 1 - 9

Thomas Edward Diehl, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Ozark Dr, Cuba, MO 65453 Phone: 573-885-2515    Fax: 573-885-2551

Mr. Michael Counts, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Ozark Dr, Cuba, MO 65453 Phone: 573-885-2515    Fax: 573-885-2550

Mr. John Wayne Hewkin, RPH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 N Franklin St, Cuba, MO 65453 Phone: 573-885-7212    Fax: 573-885-6798

Dr. Jamie Mabe, PHARMD. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 330 N Franklin St, Cuba, MO 65453 Phone: 573-885-0885

Jordan Robertson Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Ozark Dr, Cuba, MO 65453 Phone: 573-885-2515

Shayla M Farris Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 200 N Franklin St, Cuba, MO 65453 Phone: 573-885-7212

Kaitlyn Laboube, PHARM. D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Ozark Dr, Cuba, MO 65453 Phone: 573-885-2515

Hollie Lovell, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Ozark Dr, Cuba, MO 65453 Phone: 573-885-2501

Max Ruvinov Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 100 Ozark Dr, Cuba, MO 65453 Phone: 573-885-2501

News Archive

Insilico and CTFH team up to expedite first-in-class therapeutics using AI platform

Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program research collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd..

Research may offer clues to why esophageal adenocarcinomas rates have increased rapidly

During the past 30 years, the number of patients with cancers that originate near the junction of the esophagus and stomach has increased approximately 600 percent in the United States. The first extensive probe of the DNA of these esophageal adenocarcinomas has revealed that many share a distinctive mix-up of letters of the genetic code, and found more than 20 mutated genes that had not previously been linked to the disease.

AGA refused permission to appeal UK Supreme Court for Figulla ASD and PFO occluder patent infringement

In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this decision. The U.K. Court of Appeal (civil division) in London announced its decision confirming that said Figulla ASD and PFO occluders do not infringe said patent.

Unituxin (dinutuximab) granted EC Marketing Authorisation for treatment of childhood neuroblastoma

United Therapeutics Corporation announced today that the European Commission (EC) has granted Marketing Authorisation for Unituxin (dinutuximab) for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).

Read more Medical News

› Verified 4 days ago